Retrospective, cohort study of real-world treatment, testing patterns, and outcomes in relapsed or refractory FLT3-mutated acute myeloid leukemia

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

13 Dec 2022 Results assessing baseline characteristics, treatment patterns, overall survival (OS), and time to next treatment (TTNT) among FLT3+ R/R AML pts using a heavily community focused real-world dataset presented at the 64th American Society of Hematology Annual Meeting and Exposition
10 Jan 2021 New trial record
08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com